Corrigendum: Clinical manifestations of Kaposi sarcoma herpesvirus lytic activation: multicentric Castleman disease (KSHV–MCD) and the KSHV inflammatory cytokine syndrome

A corrigendum on
Clinical manifestations of Kaposi sarcoma herpesvirus lytic activation: multicentric Castleman disease (KSHV–MCD) and the KSHV inflammatory cytokine syndrome

by Polizzotto, M. N., Uldrick, T. S., Hu, D., and Yarchoan, R. (2012). Front. Microbiol. 3:73. doi: 10.3389/fmicb.2012.00073

In the original article, there was a mistake in Table 2 as published. The units for C reactive protein, ≥3 g/dL, were incorrect, and in fact, because different laboratories have different normal ranges for C reactive protein, we are not providing a specific value. The corrected Table 2 appears below.

TABLE 2

Table 2. Proposed working case definition of KSHV inflammatory cytokine syndrome.

In addition, the copyright should be considered inaccurate and has been removed to reflect the policies of the United States Government. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

The original article has been updated.

Conflict of Interest Statement

The spouse of one of the authors has patents on an assay to measure KSHV vIL-6. These inventions were made as a full-time employee of the US government under 45 Code of Federal Regulations Part 7. All rights, title, and interest to these patents have been assigned to the U.S. Department of Health and Human Services. The government conveys a portion of the royalties it receives to its employee inventors under the Federal Technology Transfer Act of 1986 (P.L. 99–502).